iRhythm Technologies Announces Third Quarter 2017 Financial Results and Raises Guidance for Full Year 2017

San Francisco, California, UNITED STATES

SAN FRANCISCO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three and nine months ended September 30, 2017.

Recent Highlights

  • Revenue for the quarter ended September 30, 2017 increased 49% year-over-year to $25.0 million
  • Gross margin for the third quarter 2017 was 72% versus 69% in the third quarter of 2016

“Third quarter and year-to-date performance highlight the progress we are making in establishing our Zio Service as the new standard of care for ambulatory cardiac monitoring,” said Kevin King, CEO. "This consistent growth in demand has enabled us to confidently expand our salesforce and infrastructure throughout 2017, as well as make significant progress in growing in-network coverage, which has meaningfully increased our productivity and volume.”

Third Quarter Financial Results
Revenue for the three months ended September 30, 2017 was $25.0 million, an increase of 49% year-over-year and 5% sequentially.  Revenue growth remains predominantly driven by increased volume of the Zio Service in both new and existing accounts, as well as continued success with in-network contracting efforts.  

Gross profit for the third quarter of 2017 was $18.1 million, or 72% gross margin, up from $11.5 million, or 69% gross margin, in the same period of the prior year. Margin expansion is primarily attributable to productivity gains through the company’s machine-learned algorithms associated with report generation, the impact from the mix shift to contracted claims, and continued reduction of device-related manufacturing costs. 

Operating expenses for the third quarter of 2017 were $24.1 million, an increase of 70% compared to $14.2 million for the same period of the prior year. The increase in operating expenses was primarily driven by accelerated salesforce expansion investments and a material increase in stock-based compensation.

Loss from operations for the third quarter of 2017 was $6.5 million, compared to $4.1 million for the same period of the prior year.

Cash, cash equivalents, and investments totaled $107.4 million as of September 30, 2017.

Guidance for Full Year 2017
iRhythm projects revenue for the full year 2017 to range from $96 to $97 million, gross margins for the full year 2017 to range from 71.5% to 72.5% and operating expenses for the full year 2017 to be between $93 and $95 million. This compares to previous guidance of $94 to $96 million in revenue, 71.5% to 72.5% in gross margins, and $89 and $92 million in operating expenses for the full year 2017 provided on August 2, 2017. 

Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at 1:30 p.m. PT / 4:30 p.m. ET. Investors interested in listening to the conference call may do so by dialing (844) 348-0016 for domestic callers or (213) 358-0876 for international callers, and referencing Conference ID: 96279903 or from the webcast on the “Investor Relations” section of the company’s website at:

About iRhythm Technologies, Inc. 
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding expectations for expansion in our salesforce, increases in our in-network contracting and financial guidance. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our Form 10-Q filing made with the Securities and Exchange Commission on August 7, 2017. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. iRhythm disclaims any obligation to update these forward-looking statements.

Investor Relations Contact:                                                Media Contact
Lynn Pieper Lewis or Leigh Salvo                                          Aaron Murphy 
(415) 937-5404                                                                       (415) 229-3331                                        

Condensed Consolidated Balance Sheets
(In thousands)

  September 30, 2017 December 31, 2016
Current assets:    
Cash and cash equivalents $  20,429  $  51,643 
Short-term investments  87,017    54,407 
Accounts receivable, net  12,039    9,406 
Inventory  1,314    1,390 
Prepaid expenses and other current assets  1,989    1,671 
Restricted cash      91 
Total current assets  122,788    118,608 
Investments, long-term      10,981 
Property and equipment, net  6,207    4,653 
Goodwill  862    862 
Other assets  3,798    3,052 
Total assets
Liabilities, Convertible Preferred Stock and Stockholders’ Equity    
Current liabilities:    
Accounts payable $  2,076  $  2,103 
Accrued liabilities  11,436    10,165 
Deferred revenue  904    947 
Accrued interest, current portion  149    — 
Debt, current portion  1,479    — 
Total current liabilities  16,044    13,215 
Debt  32,053    32,227 
Deferred rent, noncurrent portion  169    26 
Accrued interest, net of current portion      126 
Total liabilities  48,266    45,594 
Stockholders’ equity:    
Common stock  28    22 
Additional paid-in capital  230,831    219,718 
Accumulated other comprehensive loss  (30)   (9)
Accumulated deficit  (145,440)   (127,169)
Total stockholders’ equity  85,389    92,562 
Total liabilities and stockholders’ equity $  133,655  $  138,156 

Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)

 Three Months Ended
September 30,
 Nine Months Ended
September 30,
  2017   2016   2017   2016 
Revenue$  25,035  $  16,780  $  70,327  $  45,368 
Cost of revenue  6,920    5,282    20,002    15,097 
Gross profit  18,115    11,498    50,325    30,271 
Operating expenses:       
Research and development  3,790    1,635    9,187    4,847 
Selling, general and administrative  20,308    12,529    57,787    36,658 
Total operating expenses  24,098    14,164    66,974    41,505 
Loss from operations  (5,983)   (2,666)   (16,649)   (11,234)
Interest expense  (862)   (807)   (2,522)   (2,388)
Other expense, net  321    (602)   900    (1,015)
Net loss$  (6,524) $  (4,075) $  (18,271) $  (14,637)
Net loss per common share, basic and diluted$  (0.29) $  (2.80) $  (0.81) $  (10.20)
Weighted-average shares used to compute net loss per common share, basic and diluted  22,811,907    1,454,307    22,446,399    1,434,583